Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$161.50
-2.7%
$168.20
$122.14
$186.12
$16.42B0.391.21 million shs1.29 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$327.53
+1.4%
$293.98
$253.95
$385.22
$35.94B0.49280,739 shs476,546 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$16.72
+1.0%
$16.29
$12.99
$18.90
$53.57B-0.083.18 million shs4.86 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.74
+0.9%
$33.24
$15.75
$37.35
$39.94B0.867.27 million shs4.96 million shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
-0.10%-9.17%-4.71%+12.95%+29.69%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+2.94%-2.25%+8.52%+3.09%+6.15%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-1.60%-5.66%-0.96%-0.78%+16.19%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.09%+8.21%-0.39%-5.35%+119.24%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$161.50
-2.7%
$168.20
$122.14
$186.12
$16.42B0.391.21 million shs1.29 million shs
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$327.53
+1.4%
$293.98
$253.95
$385.22
$35.94B0.49280,739 shs476,546 shs
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$16.72
+1.0%
$16.29
$12.99
$18.90
$53.57B-0.083.18 million shs4.86 million shs
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$34.74
+0.9%
$33.24
$15.75
$37.35
$39.94B0.867.27 million shs4.96 million shs
10 Best Stocks to Own - Summer 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
-0.10%-9.17%-4.71%+12.95%+29.69%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
+2.94%-2.25%+8.52%+3.09%+6.15%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-1.60%-5.66%-0.96%-0.78%+16.19%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
+0.09%+8.21%-0.39%-5.35%+119.24%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2.96
Moderate Buy$201.5024.77% Upside
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
2.88
Moderate Buy$394.0020.29% Upside
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
2.00
HoldN/AN/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
2.90
Moderate Buy$42.0020.92% Upside

Current Analyst Ratings Breakdown

Latest NBIX, TAK, TEVA, and ONC Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
8/3/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$200.00 ➝ $210.00
8/3/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$200.00 ➝ $213.00
8/3/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOutperform$185.00 ➝ $194.00
7/31/2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
UpgradeSell (D-)Hold (C-)
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$246.00 ➝ $249.00
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOutperform$195.00 ➝ $198.00
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetEqual Weight$193.00 ➝ $196.00
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$200.00 ➝ $220.00
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOverweight$210.00 ➝ $215.00
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetOverweight$207.00 ➝ $210.00
7/31/2026
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
Boost Price TargetBuy$188.00 ➝ $215.00
(Data available from 8/5/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$2.86B5.74$4.87 per share33.16$36.34 per share4.44
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$5.34B6.73$4.08 per share80.28$39.77 per share8.24
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$28.32B1.89$3.08 per share5.42$14.86 per share1.13
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$17.31B2.31$3.76 per share9.24$6.75 per share5.15
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
$478.60M$6.8223.6816.200.6320.91%22.43%15.64%N/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$286.93M$4.4773.2730.87N/A8.94%12.06%6.69%8/5/2026 (Confirmed)
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
-$1.01B$0.3449.1711.15N/A3.80%10.95%5.34%N/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.41B$0.6057.8911.433.644.08%32.64%6.34%N/A

Latest NBIX, TAK, TEVA, and ONC Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/5/2026Q2 2026
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
$1.40$2.05+$0.65$2.05N/AN/A
7/29/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$0.08$0.02-$0.06-$0.49$4.02 billion$4.14 billion
6/30/2026Q2 2026
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
N/A$0.02N/A-$0.49N/A$4.14 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/AN/AN/AN/AN/A
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
N/AN/AN/AN/AN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
$0.482.89%-6.89%141.18%N/A
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
$1.012.90%N/A168.50%N/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
N/A
1.87
1.75
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
0.20
3.64
3.27
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
0.58
1.14
0.60
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
1.56
0.88
0.67

Institutional Ownership

CompanyInstitutional Ownership
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
92.59%
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
48.55%
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
9.17%
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
54.05%
CompanyEmployeesShares OutstandingFree FloatOptionable
Neurocrine Biosciences, Inc. stock logo
NBIX
Neurocrine Biosciences
2,000101.65 million95.93 millionOptionable
BeOne Medicines Ltd. - Sponsored ADR stock logo
ONC
BeOne Medicines
12,000109.72 million102.93 millionN/A
Takeda Pharmaceutical Co. stock logo
TAK
Takeda Pharmaceutical
47,0003.20 billion3.20 billionOptionable
Teva Pharmaceutical Industries Ltd. stock logo
TEVA
Teva Pharmaceutical Industries
33,9501.15 billion1.14 billionOptionable

Recent News About These Companies

Teva's Re-Rating Still Has Room To Run
Why Teva Pharmaceutical Stock Surged This Week

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Neurocrine Biosciences stock logo

Neurocrine Biosciences NASDAQ:NBIX

$161.50 -4.56 (-2.75%)
Closing price 04:00 PM Eastern
Extended Trading
$165.80 +4.30 (+2.66%)
As of 05:40 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications. The company also has license and collaboration agreements with Heptares Therapeutics Limited; Takeda Pharmaceutical Company Limited; Idorsia Pharmaceuticals Ltd; Xenon Pharmaceuticals Inc.; Voyager Therapeutics, Inc.; BIAL Portela & Ca, S.A.; Mitsubishi Tanabe Pharma Corporation; and AbbVie Inc. The company was incorporated in 1992 and is headquartered in San Diego, California.

BeOne Medicines stock logo

BeOne Medicines NASDAQ:ONC

$327.53 +4.52 (+1.40%)
Closing price 04:00 PM Eastern
Extended Trading
$327.42 -0.10 (-0.03%)
As of 05:03 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Takeda Pharmaceutical stock logo

Takeda Pharmaceutical NYSE:TAK

$16.72 +0.16 (+0.96%)
Closing price 03:59 PM Eastern
Extended Trading
$16.74 +0.03 (+0.16%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.

Teva Pharmaceutical Industries stock logo

Teva Pharmaceutical Industries NYSE:TEVA

$34.74 +0.31 (+0.89%)
Closing price 03:59 PM Eastern
Extended Trading
$34.76 +0.03 (+0.09%)
As of 05:24 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.